Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.40 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20607437 | 0.85 | MTNR1A (0.49) | POLBCES2CES1 | |
| SCHEMBL13963557 | 0.84 | FFAR1 (0.47) | TRPA1POLBTAAR1ALDH1A1CYP3A4 | |
| Acetic Acid SCHEMBL10839331 | 0.83 | RIPK1 (0.50) | RIPK1TRPA1POLBTAAR1MEN1 | |
| Hydrogen Peroxide SCHEMBL2352060 | 0.82 | RIPK1 (0.57) | RIPK1TRPA1TAAR1 | |
| SCHEMBL2091300 | 0.81 | TAAR1 (0.50) | RIPK1TRPA1TAAR1CYP1A2KMT2A | |
| SCHEMBL21148546 | 0.81 | TAAR1 (0.50) | RIPK1TRPA1TAAR1CYP1A2KMT2A | |
| SCHEMBL8673121 | 0.81 | RIPK1 (0.52) | RIPK1TRPA1TAAR1ALDH1A1CYP1A2 | |
| SCHEMBL242853 | 0.81 | RIPK1 (0.52) | RIPK1TRPA1TAAR1ALDH1A1CYP1A2 | |
| SCHEMBL10042378 | 0.81 | RIPK1 (0.52) | RIPK1TRPA1TAAR1ALDH1A1CYP1A2 | |
| SCHEMBL10552242 | 0.81 | CYP2C19 (0.46) | POLBCES2CES1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004052883-A2 | PROCESS FOR THE SEPARATION OF ENANTIOMERS | HONEYWELL INTERNATIONAL INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040110957-A1 | Process for the synthesis of an antiviral compound | HONEYWELL INTERNATIONAL, INC. (US) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110957-A1 | Process for the synthesis of an antiviral compound | EIF2AK2, IRF3, RTF1 | RIPK1 388/4885TRPA1 4218/4885POLB 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.